Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kenneth Nahum (NPI 1922079904)

Field	Value
Entity Type	Individual
Organization	Kenneth Nahum
Address	4632 Route 9 S
City	Howell
State	NJ
ZIP	07731
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 30, 2006

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider is effectively single-payer in the available claims data: lifetime Medicare revenue is $3.2M and there is no Medicaid billing on file. The top 3 Medicare codes by revenue account for 68.2% of this provider's total Medicare revenue, indicating the practice’s Medicare activity is highly concentrated in a small set of services.

Revenue is dominated by high-cost oncology infusions: J9271 (Injection, pembrolizumab, 1 mg) drives $1.2M (38.1% of Medicare revenue), J9299 (Injection, nivolumab, 1 mg) contributes $739.7K (23.4%), and J0897 (Injection, denosumab, 1 mg) contributes $213.8K (6.8%). These three drug codes together account for the precomputed 68.2% concentration, which points to a service-line centered on immune checkpoint inhibitors and bone-modifying therapy typical of medical oncology infusion practices.

Although the top drug codes generate the bulk of revenue, the provider’s national competitive standing for those drugs is not dominant: J9271 ranks #157 of 1841 providers nationally (91th percentile; typical, unremarkable volume for this code), J9299 ranks #75 of 505 providers nationally (85th percentile; typical, unremarkable volume for this code), and J0897 ranks #851 of 10057 providers nationally (92th percentile; typical, unremarkable volume for this code). In plain terms, the practice participates meaningfully in high-cost immunotherapy billing but does not appear as a national outlier or monopoly for these agents.

Visit and administration codes show unusually high utilization relative to national peers, consistent with high outpatient throughput: 99214 is reported at 1.9K claims and $192.7K revenue (6.1%) and is labeled an extreme outlier (ranks #1759 of 479517 providers nationally, 100th percentile), while 99213 is 1.1K claims and $77.7K revenue (2.5%) and is also an extreme outlier (99th percentile). Additional infusion-adjacent codes such as 96367 (1.3K claims, $33.2K, 1.1%) are also extreme outliers (99th percentile), and chemotherapy administration code 96413 (813 claims, $92.7K, 2.9%) ranks notably above typical national volume (98th percentile), underscoring strong visit and infusion throughput beyond drug billing alone.

The practice shows adoption of biosimilars and supportive-care injectables alongside branded immunotherapies: Q5119 (rituximab biosimilar ruxience) generated $86.9K (2.7%) and ranks #31 of 335 providers nationally (91th percentile; typical, unremarkable), Q5111 (pegfilgrastim-cbqv, udenyca) generated $58.3K (1.8%) and ranks #54 of 123 providers (55th percentile; typical), and Q5106 (epoetin alfa-epbx, retacrit) generated $20.5K (0.6%) and ranks #224 of 695 providers (68th percentile; typical). This mix indicates the practice uses both growth factor/ESA support and biosimilar agents as part of its oncology supportive-care portfolio.

Ancillary in-office services and procedural care are present and sometimes elevated: routine lab and venipuncture codes such as 85025 (3.6K claims, $29.2K, 0.9%) and 36415 (3.9K claims, $30.9K, 1.0%) appear at substantial volume (both described as typical, unremarkable for national peers), while a targeted therapeutic procedure 99195 (219 claims, $16.9K, 0.5%) ranks #6 of 1009 providers nationally (100th percentile; notably above typical national volume), suggesting the provider performs specialized blood removal interventions at rates well above peers.

Tenure and stability in Medicare billing are long-running: the NPI was enumerated 2006-01-30 (~20 years ago), and the lifetime Medicare activity totaling $3.2M across infusion drugs, E/M visits, chemotherapy administration, and supportive care suggests an established oncology practice with sustained Medicare caseload. The combination of long tenure and concentrated revenue in high-cost immunotherapy agents points to a mature outpatient infusion-based oncology operation with consistent Medicare engagement.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

51 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	28,000	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	30,820	$20	$739.7K
J0897	Injection, denosumab, 1 mg	11,880	$20	$213.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,850	$100	$192.7K
J1437	Injection, ferric derisomaltose, 10 mg	8,000	$20	$136K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$110	$92.7K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,780	$20	$86.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,140	$70	$77.7K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	540	$110	$58.3K
99232	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or…	890	$70	$57.9K

Showing 1–10 of 51

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 51 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Kenneth Nahum — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

51 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	50	10,650	$40	$580.7K
J9299	2	10	23,410	$20	$565.3K
Q5119	2	10	3,620	$20	$98.7K
J0897	27	380	3,060	$20	$87.8K
J1437	6	30	4,000	$20	$78.6K
Q5111	25	50	580	$110	$76.6K
J3490	3	120	70	$230	$30.2K
Q5106	29	50	3,820	$10	$30K
J0885	30	70	3,900	$10	$28.8K
96413	9	230	190	$110	$26.6K

Showing 1–10 of 51

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kenneth Nahum, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Glen Gejerman	NJ	Radiation Oncology Physician	$6.5M	$0
Bhavesh Balar	NJ	Hematology & Oncology Physician	$4.2M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
May Abdo-matkiwsky	NJ	Hematology & Oncology Physician	$2.6M	$0
Denis Fitzgerald	NJ	Hematology & Oncology Physician	$2.3M	$0
Gurpreet Lamba	VT	Hematology & Oncology Physician	$2.2M	$0
Jeffrey Silberberg	NJ	Hematology & Oncology Physician	$2M	$0
Victor Aviles	MA	Hematology & Oncology Physician	$1.8M	$0
James Xu	MD	Hematology & Oncology Physician	$1.6M	$0
Jaffar Hilli	MO	Hematology & Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Kenneth Nahum, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Eihab Human Services New Jersey, Inc.	NJ	In Home Supportive Care Agency	$0	$171.1M
Towne Pediatric Homecare LLC	NJ	Home Health Agency	$0	$16M
New Jersey Podiatric Physicians & Surgeons Group, LLC	NJ	Podiatrist	$0	$7.2M
Jeffrey Koretzky	NJ	Internal Medicine Physician	$256.7K	$0
Mohit Kapoor	NJ	Optometrist	$21.6K	$228.7K
David Lombardi	NJ	Internal Medicine Physician	$205.3K	$0
Jennifer Bannon	NJ	Family Nurse Practitioner	$166.7K	$0
Xiaoming Liu	NJ	Internal Medicine Physician	$138.5K	$0
Mark Cattell	NJ	Physician Assistant	$109.6K	$0
Jessica Addeo	NJ	Primary Podiatric Medicine Podiatrist	$74.7K	$0

Kenneth Nahum — Billing Profile & Reimbursement Data

Sign up for Kenneth Nahum — Billing Profile & Reimbursement Data policy alerts

Kenneth Nahum — Billing Profile & Reimbursement Data

Sign up for Kenneth Nahum — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References